Synthesis of new potential anticancer agents based on 4-thiazolidinone and oleanane scaffolds

Medicinal Chemistry Research

Volumn 21, Issue 11, 2012, Pages 3568-3580

  Kaminskyy, Danylo ^a   Bednarczyk Cwynar, Barbara ^a,b   Vasylenko, Olexandr ^c   Kazakova, Oxana ^d   Zimenkovsky, Borys ^a   Zaprutko, Lucjusz ^b   Lesyk, Roman ^a  

^a DANYLO HALYTSKY LVIV NATIONAL MEDICAL UNIVERSITY   (Ukraine)

^b POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^c INSTITUTE OF BIOORGANIC CHEMISTRY AND PETROCHEMISTRY   (Ukraine)

^d INSTITUTE OF ORGANIC CHEMISTRY   (Russian Federation)

Author keywords

3 Hydroxyimino oleananes; 4 Thiazolidinone 3(5) carboxylic acids; Anticancer activity

Indexed keywords

12ALPHA BROMO 3 (2,4 THIAZOLIDINEDIONE 5 ACETYLOXYIMINO) OLEAN 28BETA - 13BETA OLIDE; 12ALPHA BROMO 3 [(2,4 THIAZOLIDINEDIONE 5 YLIDENE) CARBOXYLIMINO]OLEAN 28BETA - 3BETA OLIDE; 3 (2,4 THIAZOLIDINEDIONE 3 ACETYLOXYIMINO) OLEAN 12 EN 28 OIC ACID METHYL ESTER; 3 (2,4 THIAZOLIDINEDIONE 5 ACETYLOXYIMINO) OLEAN 12 EN 28 OIC ACID; 3 (2,4 THIAZOLIDINEDIONE 5 ACETYLOXYIMINO) OLEAN 12 EN 28 OIC ACID METHYL ESTER; 3 (2,4 THIAZOLIDINEDIONE 5 ACETYLOXYIMINO) OLEAN 12 EN 28 OIC ACID MORPHOLIDE; 3 (5 ETHYLRHODANINE 3 ACETYLOXYIMINO) OLEAN 12 EN 28 OIC ACID; 3 (5 ETHYLRHODANINE 3 ACETYLOXYIMINO) OLEAN 12 EN 28 OIC ACID METHYL ESTER; 3 (RHODANINE 3 ACETYLOXYIMINO) OLEAN 12 EN 28 OIC ACID; 3 (RHODANINE 3 HEXANOYLOXYIMINO) OLEAN 12 EN 28 OIC ACID METHYL ESTER; 3 (RHODANINE 3 PROPIONYLOXYIMINO) OLEAN 12 EN 28 OIC ACID METHYL ESTER; 3 (RHODANINE 5 ACETYLOXYIMINO) OLEAN 12 EN 28 OIC ACID METHYL ESTER; 3 [(2,4 THIAZOLIDINEDIONE 5 YLIDENE) CARBOXYLIMINO]OLEAN 12 EN 28 OIC ACID METHYL ESTER; 3 [(2,4 THIAZOLIDINEDIONE 5 YLIDENE) CARBOXYLIMINO]OLEAN 12 EN 28 OIC ACID MORPHOLIDE; 3 [5 (4 METHOXYPHENYLMETHYLIDENE) RHODANINE 3 ACETYLOXYIMINO] OLEAN 12 EN 28 OIC; 3 [5 [4 (N,N DIMETHYL)AMINOPHENYLMETHYLIDENE] RHODANINE 3 ACETYLOXYIMINO] OLEAN 12 EN 28 OIC ACID METHYL ESTER; 4 THIAZOLIDINONE DERIVATIVE; OLEANOLIC ACID DERIVATIVE; OXIME DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOLOGICAL ACTIVITY; BREAST CANCER; CARBON NUCLEAR MAGNETIC RESONANCE; CENTRAL NERVOUS SYSTEM TUMOR; COLON CANCER; CONCENTRATION RESPONSE; DRUG DESIGN; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INFRARED SPECTROSCOPY; KIDNEY CANCER; LEUKEMIA; LUNG NON SMALL CELL CANCER; MELANOMA; NEOPLASM; OVARY CANCER; PROSTATE CANCER; PROTON NUCLEAR MAGNETIC RESONANCE; STRUCTURE ACTIVITY RELATION;

EID: 84871459189     PISSN: 10542523     EISSN: 15548120     Source Type: Journal    
DOI: 10.1007/s00044-011-9893-9     Document Type: Article

References (43)

1. Bodor N (1984) Novel approaches to the design of safer drugs: soft drugs and chemical deliver systems. In: Testa B (ed) Advances in drug research. Academic Press, Orlando, pp 255-331
2. Boyd MR (1997) In: Teicher BA (ed) Cancer drug discovery and development. Humana Press, Totowa, pp 23-43
3. Boyd MR, Paull KD (1995) Some practical considerations and applications of the national cancer institute in vitro anticancer drug discovery screen. Drug Dev Res 34:91-109
4. Brier S, Lemaire D, Debonis S, Forest E, Kozielski F (2004) Identification of the protein binding region of S-trityl-L-cysteine, a new potent inhibitor of the mitotic kinesin Eg5. Biochem 43:13072-13082
5. Chen J, Liu J, Zhang L, Wu G, Hua W, Wu X, Suna H (2006) Pentacyclic triterpenes. Part 3: synthesis and biological evaluation of oleanolic acid derivatives as novel inhibitors of glycogen phosphorylase. Bioorg Med Chem Lett 16:2915-2919
6. Cichewicz RH, Kouzi SA (2004) Chemistry, biological activity, and chemotherapeutic potential of betulinic acid for the prevention and treatment of cancer and HIV infection. Med Res Rev 24:90-114
7. Couch RD, Browning RG, Honda T, Gribble GW, Wright DL, Sporn MB, Anderson AC (2005) Studies on the reactivity of CDDO, a promising new chemopreventive and chemotherapeutic agent: implications for a molecular mechanism of action. Bioorg Med Chem Lett 15:2215-2219
8. Cutshall NS, O'Day C, Prezhdo M (2005) Rhodanine derivatives as inhibitors of JSP-1. Bioorg Med Chem Lett 15:3374-3379
9. Deghengni R, Daneault G (1960) Orotic acid and its analogues: part II. On the alkaline rearrangement of 5-carboxymethylidenehydantoin. Can J Chem 38:1255-1260
10. Degterev A, Lugovskoy A, Cardone M, Mulley B, Wagner G, Mitchison T, Yuan J (2001) Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xl. Nat Cell Biol 3:173-182
11. Dinkova-Kostova AT, Liby KT, Stephenson KK, Holtzclaw WD, Gao X, Suh N, Williams C, Risingsong R, Honda T, Gribble GW, Sporn MB, Talalay P (2005) Extremely potent triterpenoid inducers of the phase 2 response: Correlations of protection against oxidant and inflammatory stress. PNAS 102:4584-4589
12. Finlay HJ, Honda T, Gribble GW (2002) Synthesis of novel [3, 2-b]indole fused oleanolic acids as potential inhibitors of cell proliferation. ARKIVOC XII:38-46
13. Han SK, Ko YI, Park SJ, Jin IJ, Kim YM (1997) Oleanolic acid and ursolic acid stabilize liposomal membranes. Lipids 32:769-773
14. Havrylyuk D, Zimenkovsky B, Vasylenko O, Zaprutko L, Gzella A, Lesyk R (2009) Synthesis of novel thiazolone-based compounds containing pyrazoline moiety and evaluation of their anticancer activity. Eur J Med Chem 44:1396-1404
15. Hollingshead MG, Alley MC, Camalier RF, Abbott BJ, Mayo JG, Malspeis L, Grever MR (1995) In vivo cultivation of tumor cells in hollow fibers. Life Sci 57:131-141
16. Honda T, Gribble GW, Suh N, Finlay HJ, Rounds BV, Bore L, Favaloro FG Jr, Wang Y, Sporn MB (2000a) Novel synthetic oleanane and ursane triterpenoids with various enone functionalities in ring A as inhibitors of nitric oxide production in mouse macrophages. J Med Chem 43:1866-1877
17. Honda T, Rounds BV, Bore L, Finlay HJ, Favaloro FG Jr, Suh N, Wang Y, Sporn MB, Gribble GW (2000b) Synthetic oleanane and ursane triterpenoids with modified rings A and C: A series of highly active inhibitors of nitric oxide production in mouse macrophages. J Med Chem 43:4233-4246
18. Kaminskyy DV, Lesyk RB (2010) Structure-Anticancer activity relationships among 4-Azolidinone-3-carboxylic acids derivatives. Biopolym Cell 26:136-145
19. Kaminskyy D, Zimenkovsky B, Lesyk R (2009) Synthesis and in vitro anticancer activity of 2,4-Azolidinedione-Acetic acids derivatives. Eur J Med Chem 44:3627-3636
20. Konoki MHK, Tachibana K (1996) Cholesterol-independent membrane disruption caused by triterpenoid saponins. Biochim Biophys Acta 1299:252-258
21. Lee J, Kim J, Koh JS, Chung HH, Kim KH (2006) Hydantoin derivatives as non-peptidic inhibitors of Ras farnesyl transferase. Bioorg Med Chem Lett 16:1954-1956
22. Lesyk RB, Zimenkovsky BS (2004) 4-Thiazolidones: centenarian history, current status and perspectives for modern organic and medicinal chemistry. Curr Org Chem 8:1547-1578
23. Lesyk R, Zimenkovsky B, Troc'ko N, Kazmirchuk G (2002) Synthesis of 5-Arylidene-2,4-thiazolidin-3-yl alkanoic acids. Annal UMCS Sec DDD 15:39-45
24. Lesyk R, Zimenkovsky B, Kaminskyy D, Holota S, Atamanyuk D, Havrylyuk D, Nektegaev I, Kazmirchuk G, Subtel'na I, Roman O, Kryshchyshyn A, Khyluk D (2006) Anticancer potential of 4-Azolidones and related heterocycles. Annal UMCS Sec DDD 19:107-110
25. Lewis KG, Tucker DJ (1983) The separation of substituted olean-12-en-28-oic acid from the corresponding Urs-12-en-28-oic acid isomers. Aust J Chem 36:2297-2305
26. Liby KT, Yore MM, Sporn MB (2007) Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer. Nat Rev Cancer 7:357-369
27. Liu J (2005) Oleanolic acid and ursolic acid: research perspectives. J Ethnopharmacol 100:92-94
28. Ma C, Nakamura N, Hattori M (2000) Chemical modification of oleanene type triterpenes and their inhibitor activity against HIV-1 protease dimerization. Chem Pharm Bull (Tokoyo) 48:1681-1688
29. Ma C, Nakamura N, Hattori M, Kawahata T, Otake T (2002) Inhibitory Effects of triterpene-Azidothymidine conjugates on proliferation of human immunodeficiency virus type 1 and its protease. Chem Pharm Bull (Tokoyo) 50:877-880
30. Mallarno JP, Pilling GM, Wetzel JR, Kowalczyk PJ, Bell MR, Kullnig RK, Batzold FH, Juniewicz PE, Winneker RC, Luss HR (1992) Anti-Androgenic steroidal sulfonyl heterocycles. Utility of electrostatic complementarity in defining bioisosteric sulfonyl heterocycles. J Med Chem 35:1663-1670
31. Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D, Hose C, Langley J, Cronise P, Vaigro-Wolff A (1991) Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Nat Cancer Inst 83:757-766
32. Nair KG, Moayeri H, Mittelman A (1980) A phase II study of fluorodopan in the treatment of advanced colorectal cancer. Cancer Treat Rep 64:697-699
33. Plowman J, Dykes DJ, Hollingshead M, Simpson-Herren L, Alley MC (1997) Human tumor xenograft models in NCI drug development. In: Teicher B (ed) Anticancer drug development guide: preclinical screening, clinical trials, and approval. Humana Press, Totowa, pp 101-125
34. Popov-Pergal K, Rancic M, Pergal M, Bogdanovic G, Kojic V, Djokovic D (2006) Synthesis and biological activity evaluation of new functionally substituted 5-Arylidene-2,4-dioxotetrahydro-1,3-thiazoles. J Serb Chem Soc 71:61-866
35. Shirane N, Hashimoto Y, Ueda K, Takenaka H, Katoh K (1996) Ring-A cleavage of 3-oxo-olean-12-en-28-oic acid by the fungus chaetomium longirostre. Phytochem 43:99-104
36. Shoemaker RH (2006) The NCI 60 human tumour cell line anticancer drug screen. Nat Rev Cancer 6:813-823
37. Simonsen J, Rossk WCI (1957) The terpenes. Volume 5: The triterpenes and their derivatives. University Press, Cambridge
38. Subtel'na I, Atamanyuk D, Szyman'ska E, Kieć-Kononowicz K, Zimenkovsky B, Vasylenko O, Gzella A, Lesyk R (2010) Synthesis of 5-Arylidene-2-Amino-4-Azolones and evaluation of their anticancer activity. Bioorg Med Chem 18:5090-5102
39. Teng X, Degterev A, Jagtap P, Xing X, Choi S, Denu R, Yuan J, Cuny GD (2005) Structure-Activity relationship study of novel necroptosis inhibitors. Bioorg Med Chem Lett 15:5039-5044
40. Yakubych VY, Fedirko YaM (1983) Synthesis and properties of rhodanines synthesized base on aspartic acid. Farmacevtychnyj Zhurn (Kyiv) 5:58-60 In Ukrainian Yasue M, Sakakibara J, Kaiya T (1974) Syntheses of nitrogencontaining triterpenes. III Derivatives of betulinic acid and oleanolic acid. J Pharm Soc Jpn 94:1468-1474
41. Zaharevitz DW, Holbeck SL, Bowerman C, Svetlik PA (2002) COMPARE: A web accessible tool for investigating mechanisms of cell growth inhibition. J Mol Graphics Model 20:297-303
42. Zaprutko L, Partyka D, Bednarczyk-Cwynar B (2004) Triterpenoids. Part 21. Olenolic acid azaderivatives as perculatenous transport promoters. Bioorg Med Chem Lett 14:4723-4726
43. Zimenkovsky B, Kutsyk R, Lesyk R, Matiychuk V, Obushak N, Klyufinska T (2006) Synthesis and antimicrobial activity of 2,4-dioxothiazolidine-5-Acetic acid amides. Pharm Chem J 40: 303-306